Cargando…
Sorafenib for the treatment of unresectable hepatocellular carcinoma
Raf kinases and vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) tyrosine kinases are potential molecular targets for obtaining both anti-tumor cell progression and anti-angiogenesis effects in cancers, including hepatocellular carcinoma (HCC)....
Autor principal: | Furuse, Junji |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727884/ https://www.ncbi.nlm.nih.gov/pubmed/19707458 |
Ejemplares similares
-
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
por: Ko, Yi-Ling, et al.
Publicado: (2020) -
Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011) -
Sorafenib plus transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Tsilimigras, Diamantis I., et al.
Publicado: (2020) -
Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs
por: Marconato, Laura, et al.
Publicado: (2020) -
Durable objective response to sorafenib and role of sequential
treatment in unresectable hepatocellular carcinoma
por: Huang, Kuo-Wei, et al.
Publicado: (2022)